emperor-preserved-kidney-subanalysis
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease statusIn a new sub-analysis of the landmark EMPEROR-Preserved ®Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m21 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2021 Category: Research Source Type: news

Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim gets interim injunction against Dr. Reddy ’s Labs, MSN Labs against copies of anti-diabetes drug
In a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceutical manufacturers from launching, making, using, offering for sale, selling, importing and/or exporting their respective generic version of empagliflozin drugs. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 26, 2021 Category: Pharmaceuticals Source Type: news

MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battle
Earlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF
Groundbreaking results from the EMPEROR-Preserved trial have helped catalyze a paradigm shift in how thought leaders view ejection fraction in making important distinctions among HF patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure
Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle
The EMPEROR-Preserved trial of empagliflozin to treat patients with HFpEF comes with a lot more outcome analyses that also deserve attention, most notably some puzzling renal findings.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context
Javed Butler discusses the details of the trial on empagliflozin in HFpEF with Ileana Pi ña and what might be learned from the subgroup analyses.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 31, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Incremental, Not Monumental, Win for Empagliflozin in HFpEF Incremental, Not Monumental, Win for Empagliflozin in HFpEF
The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

emperor-preserved-heart-failure-full-data
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction  In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21  percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart fai...
Source: Boehringer Ingelheim Corporate News - August 27, 2021 Category: Research Source Type: news

FDA Okays Empagliflozin for HFrEF FDA Okays Empagliflozin for HFrEF
The drug is approved as a treatment for adults with heart failure with reduced ejection fraction (HFrEF) regardless of whether patients have diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 19, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves Jardiance (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction
Ridgefield, Conn. and Indianapolis, August 18, 2021– Jardiance (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 18, 2021 Category: Drugs & Pharmacology Source Type: news

EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF
The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news